160 related articles for article (PubMed ID: 34749675)
1. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
[TBL] [Abstract][Full Text] [Related]
2. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
[TBL] [Abstract][Full Text] [Related]
3. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
[TBL] [Abstract][Full Text] [Related]
4. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
5. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
[TBL] [Abstract][Full Text] [Related]
6. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
[TBL] [Abstract][Full Text] [Related]
7. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
[TBL] [Abstract][Full Text] [Related]
8. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
9. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
[TBL] [Abstract][Full Text] [Related]
10. Integration of a Relationship-focused Counseling Intervention with Delivery of the Dapivirine Ring for HIV Prevention to Women in Johannesburg: Results of the CHARISMA Pilot Study.
Montgomery ET; Roberts ST; Reddy K; Tolley E; Hartmann M; Wilson E; Mathebula F; Wagner LD; Zissette S; Lanham M; Wilcher R; Baeten JM; Palanee-Phillips T
AIDS Behav; 2022 Mar; 26(3):752-763. PubMed ID: 34546473
[TBL] [Abstract][Full Text] [Related]
11. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
[TBL] [Abstract][Full Text] [Related]
12. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE.
Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
Browne EN; Brown ER; Palanee-Phillips T; Reddy K; Naidoo L; Jeenarain N; Nair G; Husnik MJ; Singh D; Scheckter R; Soto-Torres L; Baeten JM; van der Straten A;
J Acquir Immune Defic Syndr; 2022 Aug; 90(4):418-424. PubMed ID: 35344520
[TBL] [Abstract][Full Text] [Related]
14. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
Reddy K; Mathebula F; Katz A; Luecke E; Tenza S; Palanee-Phillips T; Garcia M; Mansoor LE; Naidoo S; Morar N; Chitukuta M; Tsidya M; Montgomery ET;
AIDS Behav; 2022 Jun; 26(6):1923-1932. PubMed ID: 35064389
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.
Browne EN; Torjesen K; Mirembe BG; Palanee-Phillips T; Jeenarain N; Chitukuta M; Stoner MCD; Mansoor LE; Reddy K; Tauya TT; Naidoo L; Siva S; Richardson B; Dadabhai S; Seyama L; Soto-Torres L; van der Straten A;
AIDS Care; 2024 Jan; 36(1):80-86. PubMed ID: 37066990
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
[TBL] [Abstract][Full Text] [Related]
17. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
[TBL] [Abstract][Full Text] [Related]
18. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
[TBL] [Abstract][Full Text] [Related]
19. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034
[TBL] [Abstract][Full Text] [Related]
20. Implementation of a Novel Adherence Monitoring Strategy in a Phase III, Blinded, Placebo-Controlled, HIV-1 Prevention Clinical Trial.
Husnik MJ; Brown ER; Marzinke M; Livant E; Palanee-Phillips T; Hendrix CW; Matovu Kiweewa F; Nair G; Soto-Torres LE; Schwartz K; Hillier SL; Baeten JM;
J Acquir Immune Defic Syndr; 2017 Nov; 76(3):330-337. PubMed ID: 28746164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
